KWANGDONG PHARM is a pharmaceutical and food & beverage company established in 1963. The company operates through three main business segments: OTC pharmacy sales, ETC hospital sales, and F&B. Its OTC portfolio includes traditional Korean medicine products such as Ssanghwatang, Cheongsimwon, Gyeongokgo, and Gongjindan. The ETC segment covers prescription drugs, including vaccines, anticancer agents, and other specialty pharmaceuticals. The F&B segment features major brands like Vita 500, Jeju Samdasoo, corn silk tea, and hawthorn tea. The company serves the domestic market, with the majority of revenue generated from South Korea, and distributes products through pharmacies, hospitals, and retail channels. It maintains manufacturing facilities in Pyeongtaek and engages in research and development for new pharmaceuticals and functional foods. KWANGDONG PHARM has established partnerships with global pharmaceutical companies for co-promotion and license-in agreements to expand its specialty drug portfolio.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage ekdp.com
Sector Healthcare IR page —
Tags
traditional korean medicine, vaccines, vitamin c drinks, functional beverages, specialty pharmaceuticals, healthcare, otc drugs, etcs, food and beverage, pharmaceutical manufacturing, Ssanghwatang, Cheongsimwon, Gyeongokgo, Gongjindan, Vita 500, Jeju Samdasoo, Corn Silk Tea, Hawthorn Tea, Bion, Cofolang, Sunkist, Benitol, Prito, Cetraxal Plus, Revocovi, Mycapssa, Myalept, Juxtapid, Filsuvez, Brimochol, Raxone, Elfabrio, Lamzede, NVK002, ATB-346, Vyleesi, KD101, KD-BMT-301, OCU-400
Press page —

Metrics

Valuation  
Market cap ₩ 581.263B
Market cap (USD) $ 427.8M
P/E 23.11
PEG —
P/BV 0.91
P/S 0.34
P/OCF 32.87
P/FCF 118.92
Dividend yield —
Turnover / mcap —
Returns  
ROE 3.4%
ROI 3.2%
ROIC 3.3%
Profit margin 1.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -4.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -6.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.66T 1.641T 1.514T 1.432T 1.338T 1.244T 1.238T 1.18T 1.142T 1.056T 955.454B 522.274B 468.385B
Net profit 20.968B 40.481B 36.966B 24.174B 24.019B 45.37B 23.058B 22.345B 23.196B 28.063B 35.015B 35.044B 22.037B
Free cash flow 57.145B -87.883B -46.515B 37.539B 31.145B 17.566B 16.648B 34.27B 9.391B 10.655B 14.116B 14.335B 27.504B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price — — — — — 11.672K — — — — — — —
P/E — — — — — 10.43 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 213B 228B 215B 236B 257B 242B 228B 263B 318B 281B
↳ YoY growth -5.8% +6.8% -5.6% +9.6% +8.6% -5.7% -5.8% +15.4% +20.9% -11.6%
↳ 5y CAGR +20.8% +22.7% +2.5% +2.5% 0.0% +4.1% +6.1% +1.8%
Borrowings, current (KRW) 70.9B 99.6B 86.3B 85.5B 94.1B — 114B 214B 215B 239B
Borrowings, non-current (KRW) 29B 10.7B 15.3B 26.7B 15.6B — 23.6B 21.7B 74.5B 67.4B
Cash and deposits (KRW) 42.7B 47.6B 67.5B 76.3B 54.9B 84B 104B 77.3B 116B 141B
Intangible assets (KRW) 28.3B 27.3B 21.7B 16.4B 12.4B 16.7B 16.1B 36.7B 37.6B 49.2B
Net debt (borrowings + leases - cash) (KRW) -13.7B 62.7B 34.1B 35.9B 54.8B — 34.5B 158B 173B 165B
Cash flow detail
Operating cash flow (KRW) 28.8B 23.5B 53.1B 29.3B 22.8B 54.9B 62.8B -11.7B -12.2B 82.3B
Purchases of property, plant and equipment (KRW) -18.1B -14.1B -18.8B -12.6B -5.26B -23.8B -25.3B -34.8B -75.7B -25.2B
Purchases of intangible assets (KRW) 0.00 -4.02B -318M -45M -40.8M -652M -657M -373M -2.06B -1.18B
Dividends paid (cash effect) (KRW) -3.25B -3.25B -3.25B -3.21B -3.17B -4.11B -4.11B -4.11B -4.01B -3.93B
Share buybacks (cash effect) (KRW) 0.00 0.00 -2.79B -4.32B 0.00 — 0.00 -6.23B -4.07B -364M
Interest paid (cash effect) (KRW) -2.6B -2.44B -2.77B -3.17B -2.53B -2.37B -3.75B -7.51B -11.7B -10.6B
Income taxes paid (cash effect) (KRW) -16.7B -12.4B -13B -12.5B -14.2B -11.4B -13.7B -10.4B -13.6B -8.78B
Free cash flow (OCF - PPE - intangibles) (KRW) 10.7B 5.37B 34B 16.6B 17.5B 30.5B 36.9B -46.9B -89.9B 56B
Income detail
Total comprehensive income (KRW) 25.5B 20B 19.6B 24.1B 49B 29.2B 23.9B 40.2B 41.5B 20.1B
Comprehensive income to owners (KRW) 25.8B 20.4B 20B 24.4B 49B 25.6B 22.2B 37.6B 39.8B 19.1B
Reported Nov 14, 2017 Mar 29, 2019 Mar 29, 2019 Mar 30, 2020 Apr 5, 2021 Mar 22, 2024 Mar 25, 2025 Mar 25, 2025 Mar 25, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

결산실적공시예고(안내공시) Bull 0 Bear 0 Routine
주식등의대량보유상황보고서(일반) Bull 0 Bear 0 Routine

Prompts

KWANGDONG PHARM (ticker 009290), listed in South Korea.

ETFs Holding KWANGDONG PHARM

ETF Weight in ETF Shares Market value As of
DEXC 0.01% 2,822 $ 13.426K Nov 12, 2026
DFSE 0.00% 4,798 $ 22.828K Nov 12, 2026
DFEV 0.00% 16,948 $ 80.635K Nov 12, 2026
DFEM 0.00% 37,986 $ 180.729K Nov 12, 2026
DFAE 0.00% 38,213 $ 181.809K Nov 12, 2026
DFAX 0.00% 27,894 $ 132.714K Nov 12, 2026